TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production

Journal of Immunology

Volumn 182, Issue 7, 2009, Pages 4471-4478

  Chiron, David ^a,b   Pellat Deceunynck, Catherine ^a,b   Amiot, Martine ^a,b   Bataille, Régis ^a,b   Jego, Gaëtan ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR 3; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; TLR3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DEREGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR GROWTH; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERFERON-ALPHA; LIGANDS; MULTIPLE MYELOMA; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; POLY I-C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 64249114110     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803113     Document Type: Article

References (51)

1. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6: 823-835. (Pubitemid 44631651)
3. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995. (Pubitemid 41057715)
4. Chen, Y. C., E. Giovannucci, R. Lazarus, P. Kraft, S. Ketkar, and D. J. Hunter. 2005. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 65: 11771-11778. (Pubitemid 41821739)
5. Kelly, M. G., A. B. Alvero, R. Chen, D. A. Silasi, V. M. Abrahams, S. Chan, I. Visintin, T. Rutherford, and G. Mor. 2006. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66: 3859-3868.
6. Huang, B., J. Zhao, S. Shen, H. Li, K. L. He, G. X. Shen, L. Mayer, J. Unkeless, D. Li, Y. Yuan, et al. 2007. Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res. 67: 4346-4352. (Pubitemid 46815083)
7. Xiao, H., M. F. Gulen, J. Qin, J. Yao, K. Bulek, D. Kish, C. Z. Altuntas, D. Wald, C. Ma, H. Zhou, et al. 2007. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26: 461-475. (Pubitemid 46602997)
8. Chen, R., A. B. Alvero, D. A. Silasi, K. D. Steffensen, and G. Mor. 2008. Cancers take their Toll: the function and regulation of Toll-like receptors in cancer cells. Oncogene 27: 225-233.
9. Chiron, D., I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego. 2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213.
10. Jego, G., R. Bataille, A. Geffroy-Luseau, G. Descamps, and C. Pellat-Deceunynck. 2006. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20: 1130-1137. (Pubitemid 43797308)
11. Bohnhorst, J., T. Rasmussen, S. H. Moen, M. Flottum, L. Knudsen, M. Borset, T. Espevik, and A. Sundan. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144. (Pubitemid 43797309)
12. Liu, J., A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304. (Pubitemid 47026847)
13. Landgren, O., J. S. Rapkin, L. Mellemkjaer, G. Gridley, L. R. Goldin, and E. A. Engels. 2006. Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica 91: 1697-1700. (Pubitemid 46032969)
14. Landgren, O., J. S. Rapkin, N. E. Caporaso, L. Mellemkjaer, G. Gridley, L. R. Goldin, and E. A. Engels. 2007. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 109: 2198-2201. (Pubitemid 46348222)
15. Blade, J., R. A. Kyle, and P. R. Greipp. 1996. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br. J. Haematol. 93: 345-351. (Pubitemid 26148738)
16. Matsumoto, M., and T. Seya. 2008. TLR3: interferon induction by doublestranded RNA including poly(I:C). Adv. Drug Delivery Rev. 60: 805-812.
17. Kariko, K., H. Ni, J. Capodici, M. Lamphier, and D. Weissman. 2004. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279: 12542-12550. (Pubitemid 38445825)
18. Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
19. Salaun, B., I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176: 4894-4901.
20. Salaun, B., S. Lebecque, S. Matikainen, D. Rimoldi, and P. Romero. 2007. Tolllike receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13: 4565-4574. (Pubitemid 47219727)
21. Morikawa, T., A. Sugiyama, H. Kume, S. Ota, T. Kashima, K. Tomita, T. Kitamura, T. Kodama, M. Fukayama, and H. Aburatani. 2007. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin. Cancer Res. 13: 5703-5709. (Pubitemid 47583894)
22. Pries, R., L. Hogrefe, L. Xie, H. Frenzel, C. Brocks, C. Ditz, and B. Wollenberg. 2008. Induction of c-Myc-dependent cell proliferation through Toll-like receptor 3 in head and neck cancer. Int. J. Mol. Med. 21: 209-215. (Pubitemid 351222854)
23. Duffy, K. E., R. J. Lamb, L. R. San Mateo, J. L. Jordan, G. Canziani, M. Brigham-Burke, J. Korteweg, M. Cunningham, H. S. Beck, J. Carton, et al. 2007. Down-modulation of human TLR3 function by a monoclonal antibody. Cell. Immunol. 248: 103-114. (Pubitemid 350299024)
24. Zhang, X. G., J. P. Gaillard, N. Robillard, Z. Y. Lu, Z. J. Gu, M. Jourdan, J. M. Boiron, R. Bataille, and B. Klein. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663.
25. Karin, M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431-436. (Pubitemid 44050137)
26. Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, and M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272: 21096-21103.
27. Crowder, C., O. Dahle, R. E. Davis, O. S. Gabrielsen, and S. Rudikoff. 2005. PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105: 1280-1287. (Pubitemid 40170904)
28. Gomez-Benito, M., P. Balsas, X. Carvajal-Vergara, A. Pandiella, A. Anel, I. Marzo, and J. Naval. 2007. Mechanism of apoptosis induced by IFN-α in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell. Signal. 19: 844-854. (Pubitemid 46275374)
29. Platanias, L. C., and E. N. Fish. 1999. Signaling pathways activated by interferons. Exp. Hematol. 27: 1583-1592.
30. Yoshimura, A. 2006. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97: 439-447. (Pubitemid 43811583)
31. Takauji, R., S. Iho, H. Takatsuka, S. Yamamoto, T. Takahashi, H. Kitagawa, H. Iwasaki, R. Iida, T. Yokochi, and T. Matsuki. 2002. CpG-DNA-induced IFN-α production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J. Leukocyte Biol. 72: 1011-1019. (Pubitemid 35365176)
32. Gilmore, T. D. 2007. Multiple myeloma: lusting for NF-κB. Cancer Cells 12: 95-97.
33. Annunziata, C. M., R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cells 12: 115-130.
34. Keats, J. J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cells 12: 131-144.
35. Li, Z. W., H. Chen, R. A. Campbell, B. Bonavida, and J. R. Berenson. 2008. NF-κB in the pathogenesis and treatment of multiple myeloma. Curr. Opin. Hematol. 15: 391-399.
36. Durie, B. G., H. B. Levy, J. Voakes, J. R. Jett, and A. S. Levine. 1985. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J. Biol. Response Modif. 4: 518-524. (Pubitemid 16241551)
37. Hasan, U. A., C. Caux, I. Perrot, A. C. Doffin, C. Menetrier-Caux, G. Trinchieri, M. Tommasino, and J. Vlach. 2007. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc. Natl. Acad. Sci. USA 104: 8047-8052.
38. Osawa, Y., S. Iho, R. Takauji, H. Takatsuka, S. Yamamoto, T. Takahashi, S. Horiguchi, Y. Urasaki, T. Matsuki, and S. Fujieda. 2006. Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells. J. Immunol. 177: 4841-4852. (Pubitemid 44469820)
39. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptordependent and -independent antiviral response. Nature 439: 208-211. (Pubitemid 43083142)
40. Hacker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Hacker, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207. (Pubitemid 43083141)
41. Panaretakis, T., L. Hjortsberg, K. P. Tamm, A. C. Bjorklund, B. Joseph, and D. Grander. 2008. Interferon α induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol. Biol. Cell 19: 41-50. (Pubitemid 351186131)
42. Arora, T., G. Floyd-Smith, M. J. Espy, and D. F. Jelinek. 1999. Dissociation between IFN-α-induced anti-viral and growth signaling pathways. J. Immunol. 162: 3289-3297. (Pubitemid 29313576)
43. Bataille, R., G. Jego, N. Robillard, S. Barille-Nion, J. L. Harousseau, P. Moreau, M. Amiot, and C. Pellat-Deceunynck. 2006. The phenotype of normal, reactive and malignant plasma cells: identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 91: 1234-1240.
44. Caraglia, M., M. Marra, G. Pelaia, R. Maselli, M. Caputi, S. A. Marsico, and A. Abbruzzese. 2005. α-Interferon and its effects on signal transduction pathways. J. Cell. Physiol. 202: 323-335. (Pubitemid 40041303)
45. Wuilleme-Toumi, S., N. Robillard, P. Gomez, P. Moreau, S. Le Gouill, H. Avet-Loiseau, J. L. Harousseau, M. Amiot, and R. Bataille. 2005. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19: 1248-1252. (Pubitemid 40946011)
46. Gomez-Bougie, P., S. Wuilleme-Toumi, E. Menoret, V. Trichet, N. Robillard, M. Philippe, R. Bataille, and M. Amiot. 2007. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67: 5418-5424. (Pubitemid 46997282)
47. Sun, Y., and D. W. Leaman. 2005. Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J. Biol. Chem. 280: 15561-15568. (Pubitemid 40616672)
48. Gomez-Bougie, P., R. Bataille, and M. Amiot. 2004. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur. J. Immunol. 34: 3156-3164. (Pubitemid 39549394)
49. Menoret, E., P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J. L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck. 2006. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108: 1346-1352. (Pubitemid 44232035)
50. Gomez-Bougie, P., L. Oliver, S. Le Gouill, R. Bataille, and M. Amiot. 2005. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene 24: 8076-8079. (Pubitemid 41746750)
51. Qin, J. Z., J. Ziffra, L. Stennett, B. Bodner, B. K. Bonish, V. Chaturvedi, F. Bennett, P. M. Pollock, J. M. Trent, M. J. Hendrix, et al. 2005. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65: 6282-6293. (Pubitemid 40994414)